Karl Oliver Kagan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7897825/publications.pdf

Version: 2024-02-01

136740 106150 4,521 107 32 citations h-index papers

65 g-index 118 118 118 3003 times ranked docs citations citing authors all docs

#	Article	IF	CITATIONS
1	<scp>ISUOG</scp> Practice Guidelines: performance of firstâ€trimester fetal ultrasound scan. Ultrasound in Obstetrics and Gynecology, 2013, 41, 102-113.	0.9	465
2	Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free betaâ€human chorionic gonadotropin and pregnancyâ€associated plasma proteinâ€A. Ultrasound in Obstetrics and Gynecology, 2008, 31, 618-624.	0.9	307
3	Firstâ€trimester screening for trisomy 21 by free betaâ€human chorionic gonadotropin and pregnancyâ€associated plasma proteinâ€A: impact of maternal and pregnancy characteristics. Ultrasound in Obstetrics and Gynecology, 2008, 31, 493-502.	0.9	256
4	A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound in Obstetrics and Gynecology, 2008, 31, 376-383.	0.9	215
5	Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free Â-hCG and pregnancy-associated plasma protein-A. Human Reproduction, 2008, 23, 1968-1975.	0.4	201
6	Ductus venosus Doppler in screening for trisomies 21, 18 and 13 and Turner syndrome at 11–13 weeks of gestation. Ultrasound in Obstetrics and Gynecology, 2009, 33, 512-517.	0.9	166
7	Discordance in nuchal translucency thickness in the prediction of severe twin-to-twin transfusion syndrome. Ultrasound in Obstetrics and Gynecology, 2007, 29, 527-532.	0.9	164
8	Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at $11 + 0$ to $13 + 6$ weeks of gestation. Ultrasound in Obstetrics and Gynecology, 2009, 33, 18-22.	0.9	146
9	Mutations in SEC24D, Encoding a Component of the COPII Machinery, Cause a Syndromic Form of Osteogenesis Imperfecta. American Journal of Human Genetics, 2015, 96, 432-439.	2.6	143
10	Relation Between Increased Fetal Nuchal Translucency Thickness and Chromosomal Defects. Obstetrics and Gynecology, 2006, 107, 6-10.	1.2	141
11	Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11–13 weeks of gestation. Ultrasound in Obstetrics and Gynecology, 2009, 33, 259-264.	0.9	136
12	How to measure cervical length. Ultrasound in Obstetrics and Gynecology, 2015, 45, 358-362.	0.9	113
13	Prospective validation of firstâ€ŧrimester combined screening for trisomy 21. Ultrasound in Obstetrics and Gynecology, 2009, 34, 14-18.	0.9	109
14	Prevention of maternal–fetal transmission of cytomegalovirus after primary maternal infectio first trimester by biweekly hyperimmunoglobulin administration. Ultrasound in Obstetrics and Gynecology, 2019, 53, 383-389.	on in the 0.9	103
15	ISUOG consensus statement on the impact of non-invasive prenatal testing (NIPT) on prenatal ultrasound practice. Ultrasound in Obstetrics and Gynecology, 2014, 44, 122-123.	0.9	96
16	The 11–13â€week scan: diagnosis and outcome of holoprosencephaly, exomphalos and megacystis. Ultrasound in Obstetrics and Gynecology, 2010, 36, 10-14.	0.9	91
17	Learning curve for Doppler assessment of ductus venosus flow at $11 + 0$ to $13 + 6$ weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2008, 31, 503-506.	0.9	77
18	<scp>ISUOG</scp> updated consensus statement on the impact of <scp>cfDNA</scp> aneuploidy testing on screening policies and prenatal ultrasound practice. Ultrasound in Obstetrics and Gynecology, 2017, 49, 815-816.	0.9	77

#	Article	lF	CITATIONS
19	Cytomegalovirus infection in pregnancy. Archives of Gynecology and Obstetrics, 2017, 296, 15-26.	0.8	64
20	Firstâ€trimester ultrasound images using HDlive. Ultrasound in Obstetrics and Gynecology, 2011, 38, 607-607.	0.9	63
21	Dose dependency between cigarette consumption and reduced maternal serum PAPP-A levels at 11–13+6 weeks of gestation. Prenatal Diagnosis, 2007, 27, 849-853.	1.1	62
22	Effect of deviation of nuchal translucency measurements on the performance of screening for trisomy 21. Ultrasound in Obstetrics and Gynecology, 2009, 33, 657-664.	0.9	59
23	Twoâ€stage firstâ€trimester screening for trisomy 21 by ultrasound assessment and biochemical testing. Ultrasound in Obstetrics and Gynecology, 2010, 36, 542-547.	0.9	52
24	Preterm birth: the value of sonographic measurement of cervical length. BJOG: an International Journal of Obstetrics and Gynaecology, 2006, 113, 52-56.	1.1	50
25	Screening for trisomy 18 by maternal age, fetal nuchal translucency, free βâ€human chorionic gonadotropin and pregnancyâ€associated plasma proteinâ€A. Ultrasound in Obstetrics and Gynecology, 2008, 32, 488-492.	0.9	47
26	Firstâ€trimester screening for trisomies 18 and 13, triploidy and Turner syndrome by detailed early anomaly scan. Ultrasound in Obstetrics and Gynecology, 2016, 48, 446-451.	0.9	46
27	Principles of first trimester screening in the age of non-invasive prenatal diagnosis: screening for chromosomal abnormalities. Archives of Gynecology and Obstetrics, 2017, 296, 645-651.	0.8	46
28	Living-Donor Uterus Transplantation: Pre-, Intra-, and Postoperative Parameters Relevant to Surgical Success, Pregnancy, and Obstetrics with Live Births. Journal of Clinical Medicine, 2020, 9, 2485.	1.0	45
29	Firstâ€trimester contingent screening for trisomies 21, 18 and 13 by fetal nuchal translucency and ductus venosus flow and maternal blood cellâ€free ⟨scp⟩DNA⟨/scp⟩ testing. Ultrasound in Obstetrics and Gynecology, 2015, 45, 42-47.	0.9	42
30	Quality Requirements for the early Fetal Ultrasound Assessment at 11–13+6 Weeks of Gestation (DEGUM Levels II and III). Ultraschall in Der Medizin, 2016, 37, 297-302.	0.8	40
31	Firstâ€trimester risk assessment based on ultrasound and cellâ€free DNA <i>vs</i> combined screening: a randomized controlled trial. Ultrasound in Obstetrics and Gynecology, 2018, 51, 437-444.	0.9	39
32	Outcome of pregnancies with recent primary cytomegalovirus infection in first trimester treated with hyperimmunoglobulin: observational study. Ultrasound in Obstetrics and Gynecology, 2021, 57, 560-567.	0.9	36
33	Novel fetal and maternal sonographic findings in confirmed cases of Beckwith–Wiedemann syndrome. Prenatal Diagnosis, 2015, 35, 394-399.	1.1	33
34	First trimester ultrasound screening for Down syndrome based on maternal age, fetal nuchal translucency and different combinations of the additional markers nasal bone, tricuspid and ductus venosus flow. Prenatal Diagnosis, 2015, 35, 1182-1186.	1.1	31
35	Intra- and interoperator reliability of manual and semi-automated measurement of fetal nuchal translucency by sonographers with different levels of experience. Ultrasound in Obstetrics and Gynecology, 2010, 36, 417-422.	0.9	29
36	Firstâ€trimester combined screening for trisomy 21 with different combinations of placental growth factor, free βâ€human chorionic gonadotropin and pregnancyâ€associated plasma proteinâ€A. Ultrasound in Obstetrics and Gynecology, 2012, 40, 530-535.	0.9	29

#	Article	IF	CITATIONS
37	The cavum septi pellucidi in euploid and aneuploid fetuses. Ultrasound in Obstetrics and Gynecology, 2013, 42, 156-160.	0.9	28
38	Inverted Pyramid of Care. Clinics in Laboratory Medicine, 2016, 36, 305-317.	0.7	27
39	Frontal space distance in facial clefts and retrognathia at 11-13 weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2016, 48, 171-176.	0.9	25
40	Effect of deviation from the mid-sagittal plane on the measurement of fetal nuchal translucency. Ultrasound in Obstetrics and Gynecology, 2010, 35, 525-529.	0.9	24
41	Antenatal screening for chromosomal abnormalities. Archives of Gynecology and Obstetrics, 2022, 305, 825-835.	0.8	24
42	Comparison of three methods of cervical measurement in the first trimester: singleâ€line, twoâ€line, and tracing. Prenatal Diagnosis, 2013, 33, 262-268.	1.1	23
43	Prefrontal space ratio in second- and third-trimester screening for trisomy 21. Ultrasound in Obstetrics and Gynecology, 2013, 41, 262-266.	0.9	23
44	Nasal bone length, prenasal thickness, prenasal thicknessâ€toâ€nasal bone length ratio and prefrontal space ratio in second―and thirdâ€trimester fetuses with Down syndrome. Ultrasound in Obstetrics and Gynecology, 2015, 45, 211-216.	0.9	22
45	Genomeâ€wide cfDNA testing of maternal blood. Ultrasound in Obstetrics and Gynecology, 2020, 55, 13-14.	0.9	22
46	Maternal Weight, Weight Gain, and Metabolism are Associated with Changes in Fetal Heart Rate and Variability. Obesity, 2020, 28, 114-121.	1.5	22
47	Confirmation rate of cell free <scp>DNA</scp> screening for sex chromosomal abnormalities according to the method of confirmatory testing. Prenatal Diagnosis, 2021, 41, 1258-1263.	1.1	22
48	Impact of bias in crown–rump length measurement at firstâ€ŧrimester screening for trisomy 21. Ultrasound in Obstetrics and Gynecology, 2012, 40, 135-139.	0.9	20
49	Screening for Chromosomal Abnormalities by First Trimester Combined Screening and Noninvasive Prenatal Testing. Ultraschall in Der Medizin, 2015, 36, 40-46.	0.8	19
50	Outcome of pregnancies with spontaneous PPROM before 24 + 0 weeks' gestation. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2016, 203, 121-126.	0.5	19
51	Factors influencing the duration of late first and second-trimester termination of pregnancy with prostaglandin derivates. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2011, 155, 75-78.	0.5	18
52	Effective management and intrauterine treatment of congenital cytomegalovirus infection: review article and case series. Journal of Maternal-Fetal and Neonatal Medicine, 2014, 27, 209-214.	0.7	17
53	Fetal facial profile markers of Down syndrome in the second and third trimesters of pregnancy. Ultrasound in Obstetrics and Gynecology, 2015, 46, 168-173.	0.9	17
54	First Trimester Screening for Common Trisomies and Microdeletion 22q11.2 Syndrome Using Cell-Free DNA: A Prospective Clinical Study. Fetal Diagnosis and Therapy, 2020, 47, 841-852.	0.6	16

#	Article	IF	CITATIONS
55	Assessment of the ductus venosus, tricuspid blood flow and the nasal bone in second-trimester screening for trisomy 21. Ultrasound in Obstetrics and Gynecology, 2011, 37, 444-449.	0.9	14
56	Screening Performance and Costs of Different Strategies in Prenatal Screening for Trisomy 21. Geburtshilfe Und Frauenheilkunde, 2015, 75, 244-250.	0.8	14
57	Rate of no result in cellâ€free <scp>DNA</scp> testing and its influence on test performance metrics. Ultrasound in Obstetrics and Gynecology, 2017, 50, 134-137.	0.9	14
58	Optimal caliper placement: manual <i>vs</i> automated methods. Ultrasound in Obstetrics and Gynecology, 2014, 43, 170-175.	0.9	12
59	False-Positive Rate in First-Trimester Screening Based on Ultrasound and Cell-Free DNA versus First-Trimester Combined Screening with Additional Ultrasound Markers. Fetal Diagnosis and Therapy, 2019, 45, 317-324.	0.6	12
60	Assessment of Foetal DNA in Maternal Blood – A Useful Tool in the Hands of Prenatal Specialists. Geburtshilfe Und Frauenheilkunde, 2012, 72, 998-1003.	0.8	11
61	Facial markers in second―and thirdâ€trimester fetuses with trisomy 18 or 13, triploidy or Turner syndrome. Ultrasound in Obstetrics and Gynecology, 2015, 46, 60-65.	0.9	11
62	Principles of first trimester screening in the age of non-invasive prenatal diagnosis: screening for other major defects and pregnancy complications. Archives of Gynecology and Obstetrics, 2017, 296, 635-643.	0.8	11
63	First trimester pregnancy volumes and subsequent small for gestational age fetuses. Archives of Gynecology and Obstetrics, 2014, 290, 41-46.	0.8	10
64	Repeat Measurement of Cervical Length in Women with Threatened Preterm Labor. Geburtshilfe Und Frauenheilkunde, 2016, 76, 779-784.	0.8	10
65	Dosing interval between mifepristone and misoprostol in second and third trimester termination. Archives of Gynecology and Obstetrics, 2019, 299, 675-679.	0.8	10
66	Fetal loss after chorionic villus sampling in twin pregnancy. Ultrasound in Obstetrics and Gynecology, 2021, 58, 48-55.	0.9	9
67	Risk of fetal loss after chorionic villus sampling in twin pregnancy derived from propensity score matching analysis. Ultrasound in Obstetrics and Gynecology, 2022, 59, 162-168.	0.9	9
68	The frontal space measurement in euploid and aneuploid pregnancies at 11–13 weeks' gestation. Prenatal Diagnosis, 2013, 33, 1124-1130.	1.1	8
69	Intraoperator and interoperator repeatability of manual and semiâ€automated measurement of increased fetal nuchal translucency according to the operator's experience. Prenatal Diagnosis, 2011, 31, 1229-1233.	1.1	7
70	Influence of Mifepristone in Induction Time for Terminations in the Second and Third Trimester. Geburtshilfe Und Frauenheilkunde, 2014, 74, 350-354.	0.8	7
71	Comparison of Errors of 35 Weight Estimation Formulae in a Standard Collective. Geburtshilfe Und Frauenheilkunde, 2016, 76, 1172-1179.	0.8	7
72	Discordance between ultrasound and cell free DNA screening for monosomy X. Archives of Gynecology and Obstetrics, 2016, 294, 219-224.	0.8	7

#	Article	IF	CITATIONS
73	Vasa previa: easy to miss. Ultrasound in Obstetrics and Gynecology, 2018, 51, 283-284.	0.9	7
74	Firstâ€trimester ductus venosus velocity ratio as a marker of major cardiac defects. Ultrasound in Obstetrics and Gynecology, 2019, 53, 663-668.	0.9	7
75	Ten reasons why we should not abandon a detailed first trimester anomaly scan. Ultraschall in Der Medizin, 2021, 42, 451-459.	0.8	7
76	Position of the conus medullaris in fetuses with skeletal dysplasia. Prenatal Diagnosis, 2012, 32, 1313-1317.	1.1	6
77	Outcome of dichorionic diamniotic twin pregnancies with spontaneous PPROM before 24 weeks' gestation. Journal of Maternal-Fetal and Neonatal Medicine, 2017, 30, 1750-1754.	0.7	6
78	Single and repeat cervicalâ€length measurement in twin gestation with threatened preterm labor. Ultrasound in Obstetrics and Gynecology, 2020, 55, 496-501.	0.9	6
79	Measurement of the uterocervical angle for the prediction of preterm birth in symptomatic women. Archives of Gynecology and Obstetrics, 2021, 304, 663-669.	0.8	6
80	Universal Cell Free DNA or Contingent Screening for Trisomy 21: Does It Make a Difference? A Comparative Study with Real Data. Fetal Diagnosis and Therapy, 2022, 49, 85-94.	0.6	6
81	Firstâ€trimester ultrasound screening for trisomy 21 based on maternal age, fetal nuchal translucency, and different methods of ductus venosus assessment. Prenatal Diagnosis, 2017, 37, 680-685.	1.1	5
82	Effectiveness of the contemporary treatment of preterm labor: a comparison with a historical cohort. Archives of Gynecology and Obstetrics, 2017, 296, 27-34.	0.8	5
83	Antenatal treatment options for primary cytomegalovirus infections. Current Opinion in Obstetrics and Gynecology, 2018, 30, 355-360.	0.9	5
84	First trimester uterine artery pulsatility index levels in euploid and aneuploid pregnancies. Archives of Gynecology and Obstetrics, 2019, 300, 1559-1564.	0.8	5
85	Measurement of Gastric Circumference in Foetuses with Oesophageal Atresia. Geburtshilfe Und Frauenheilkunde, 2015, 75, 1148-1152.	0.8	4
86	First trimester screening for major cardiac defects based on the ductus venosus flow in fetuses with trisomy 21. Prenatal Diagnosis, 2018, 38, 561-566.	1.1	4
87	False-positive rates in screening for trisomies 18 and 13: a comparison between first-trimester combined screening and a cfDNA-based approach. Archives of Gynecology and Obstetrics, 2019, 299, 431-437.	0.8	4
88	Fetal profile in fetuses with open spina bifida. Archives of Gynecology and Obstetrics, 2020, 301, 1167-1171.	0.8	4
89	How to do a second trimester anomaly scan. Archives of Gynecology and Obstetrics, 2022, , .	0.8	4
90	Splenic artery blood flow as a potential marker for materno-fetal transmission of a primary CMV infection. Archives of Gynecology and Obstetrics, 2019, 299, 1289-1294.	0.8	3

#	Article	IF	Citations
91	Fetal Costello syndrome: description of phenotype of HRAS exon 1 mutations. Ultrasound in Obstetrics and Gynecology, 2020, 55, 274-275.	0.9	2
92	Abnormal Placentation and Umbilical Cord Insertion. Ultraschall in Der Medizin, 2020, 41, 120-137.	0.8	2
93	Fetal markers for the detection of infants with craniofacial malformation. Seminars in Fetal and Neonatal Medicine, 2021, 26, 101291.	1.1	2
94	Diagnosis and treatment of twin-to-twin transfusion syndrome (TTTS). Medical Laser Application: International Journal for Laser Treatment and Research, 2009, 24, 52-56.	0.4	1
95	Maxillary length in euploid and aneuploid fetuses. Archives of Gynecology and Obstetrics, 2017, 295, 331-336.	0.8	1
96	Changes in the Detection and Management of Foetal Trisomies over Time. Geburtshilfe Und Frauenheilkunde, 2018, 78, 853-858.	0.8	1
97	Fetal Profile Markers for the Detection of Robin Sequence in Fetuses with Retrognathia. Ultraschall in Der Medizin, 2021, , .	0.8	1
98	OC26.01: Fetal weight estimation in fetuses of 1500g or less. Ultrasound in Obstetrics and Gynecology, 2009, 34, 50-51.	0.9	0
99	OP02.02: Effect of deviation of nuchal translucency measurements on the performance of screening for trisomy 21. Ultrasound in Obstetrics and Gynecology, 2009, 34, 65-65.	0.9	0
100	OP02.03: Dependency of fetal NT thickness on the position of the fetal head. Ultrasound in Obstetrics and Gynecology, 2009, 34, 65-66.	0.9	0
101	OP20.08: Holoprosencephaly, megacystis and exomphalos and the risk for chromosomal abnormalities. Ultrasound in Obstetrics and Gynecology, 2009, 34, 126-127.	0.9	0
102	P11.12: Effect of deviation of free \hat{l}^2 -hCG and PAPP-A on the performance of screening for trisomy 21. Ultrasound in Obstetrics and Gynecology, 2009, 34, 221-221.	0.9	0
103	OP03.05: Prenatal detection of closed spina bifida. Ultrasound in Obstetrics and Gynecology, 2011, 38, 64-64.	0.9	0
104	Sphenofrontal distance in euploid and aneuploid fetuses. Ultrasound in Obstetrics and Gynecology, 2017, 50, 187-191.	0.9	0
105	PrÃ ¤ atale Medizin. Springer Reference Medizin, 2020, , 509-519.	0.0	0
106	Erstes Trimenon. , 2020, , 1-50.		0
107	Präatale Medizin. Springer Reference Medizin, 2020, , 1-11.	0.0	0